- ALNY (click for stock research page) presented 10/21 at the BioCentury Newsmakers Conference (find webcast link and complete biotech webcast calendar on Upcoming Events page)
- speaker: Chief Business Officer (CBO)
- no slide deck online
- rapidly growing RNAi human database, >500 patients...gives info on efficacy, mechanism of action, phamcology, safety
- TTR02 IND "late this year"
- PCS - RNAi can reduce PCSK9 levels inside and outside of cells, which monoclonal antibody approach can't do
- Biotherapeutics program - have been "incubating this idea over last 2 years or so." Think we can improve the next generation of novel therapeutics, biobetters, and biosimilars [but doesn't sound like trying to work with partners to change production methods for current drugs]... scales nicely into bioprocessing /manufacturing systems..We plan to develop this business as go into next year as a revenue stream back into parent compnay. 2 large pharma partnerships now
- APC program is transitioning from "research" to "development" phase
- q&a in breakout session
RSS Feed
